Skip to main content

Table 1 19q12 amplification in 313 breast cancers and clinicopathological associations

From: Functional characterization of the 19q12 amplicon in grade III breast cancers

   19q12
Amp n (%)
19q12
Not amp n (%)
P-value CCNE1
Amp (%)
CCNE1
Not amp (%)
P-value
Whole cohort   16 (5.1%) 297 (94.9%) NA 5 (1.6%) 308 (98.4%) NA
Histological grade*     0.0018 +    0.1693+
  I/II 0 (0%) 109 (100%)   0 (0%) 109 (100%)  
  III 16 (8%) 188 (92%)   5 (2%) 199 (98%)  
ER     0.0042 +    0.01984 +
  Positive 3 (2%) 166 (98%)   0 (0%) 169 (100%)  
  Negative 13 (9%) 131 (91%)   5 (3.5%) 139 (96.5%)  
HER2     0.5398+    0.9801+
  Positive 2 (3%) 62 (97%)   1(1.6%) 63(98.4%)  
  Negative 14 (6%) 235 (94%)   4(1.6%) 245(98.4%)  
Subtypes     0.0056**^    0.0500**^
  ER-/HER2- 11 (11%) 90 (89%) 0.0024*** 4 (4%) 97 (96%) 0.0399***
  HER2 2 (3%) 62 (97%)   1 (2%) 63 (98%)  
  ER+/HER2- 3 (2%) 145 (98%)   0 (0%) 148 (100%)  
  1. Amp, amplified; CCNE1, cyclin E1; ER, oestrogen receptor; NA, not applicable; Not amp, not amplified.
  2. *Histological grade determined by the modified Scarff-Bloom-Richardson system [32].
  3. Significant P-values are highlighted in bold.
  4. +: Fisher's exact test
  5. **: Chi-square test
  6. ***: Comparison between ER-/HER2- vs the remaining subtypes by Fisher's exact test.
  7. ^: Given that > 20% of the groups have n < 5, the Chi-square P-value should be interpreted with caution.